| MeSH term | MeSH ID | Detail |
|---|---|---|
| Apraxias | D001072 | 1 associated lipids |
| Anus Diseases | D001004 | 3 associated lipids |
| Angioedema | D000799 | 6 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Cavaillé-Coll MW and Elashoff MR | Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. | 1998 | Transplantation | pmid:9448161 |
| Gjertson DW et al. | The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. | 1995 | Transplantation | pmid:8545861 |
| Ellis D et al. | Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10532541 |
| First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
| Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Hashimoto T et al. | Treatment with FK506 prevents rejection of rat colon allografts. | 1994 | Transplantation | pmid:7516586 |
| Jain AB et al. | Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. | 2004 | Transplantation | pmid:15077034 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Weir MR et al. | Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. | 2017 | Transplantation | pmid:26950714 |
| Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
| Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
| Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
| Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
| Bronster DJ et al. | Demyelinating sensorimotor polyneuropathy after administration of FK506. | 1995 | Transplantation | pmid:7535959 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
| Herlenius G et al. | Chronic kidney disease--a common and serious complication after intestinal transplantation. | 2008 | Transplantation | pmid:18622286 |
| Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
| Watson MJ et al. | Renal function impacts outcomes after intestinal transplantation. | 2008 | Transplantation | pmid:18622288 |
| McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
| Jun KR et al. | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 | Transplantation | pmid:19384171 |
| Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
| Inamura N et al. | Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. | 1988 | Transplantation | pmid:2447690 |
| Radkowski M et al. | Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9753352 |
| Egashira K et al. | Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. | 2003 | Transplantation | pmid:12698101 |
| Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
| Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
| Fujishiro J et al. | Immunologic benefits of longer graft in rat allogenic small bowel transplantation. | 2005 | Transplantation | pmid:15665767 |
| Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
| Holländer GA et al. | Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. | 1994 | Transplantation | pmid:7526495 |
| Gruessner RW et al. | A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. | 1996 | Transplantation | pmid:8600635 |
| Aisa Y et al. | Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. | 2005 | Transplantation | pmid:16278584 |
| Tanaka J et al. | The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. | 2005 | Transplantation | pmid:16378079 |
| Dharancy S et al. | Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. | 2007 | Transplantation | pmid:17460561 |
| Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |